Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
Duke University
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center